Telomir reports Telomir-1 significantly reduced tumor growth and spread in preclinical cancer models

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Telomir Pharmaceuticals said its investigational small-molecule therapy Telomir-1 (Zn-Telomir) produced statistically significant reductions in both primary tumor growth and metastatic dissemination in preclinical tumor xenograft models of aggressive triple-negative breast cancer (TNBC). In these animal studies, Telomir-1 lowered primary tumor burden and limited the spread of cancer cells beyond the original tumor site in models with limited responsiveness to standard chemotherapy. The compound also showed comparable tumor-growth inhibition when used alone and enhanced activity when combined with the chemotherapy drug paclitaxel, resulting in greater suppression of tumor growth than either agent alone.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Windward Bio raises $251m with Sanofi buying in

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE